IGM Biosciences (IGMS) Competitors $1.31 +0.04 (+3.15%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.28 -0.03 (-2.29%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IGMS vs. IVA, VOR, ESPR, SCPH, BNTC, HRTX, MREO, TKNO, ANNX, and LFCRShould you be buying IGM Biosciences stock or one of its competitors? The main competitors of IGM Biosciences include Inventiva (IVA), Vor Biopharma (VOR), Esperion Therapeutics (ESPR), scPharmaceuticals (SCPH), Benitec Biopharma (BNTC), Heron Therapeutics (HRTX), Mereo BioPharma Group (MREO), Alpha Teknova (TKNO), Annexon (ANNX), and Lifecore Biomedical (LFCR). These companies are all part of the "pharmaceutical products" industry. IGM Biosciences vs. Its Competitors Inventiva Vor Biopharma Esperion Therapeutics scPharmaceuticals Benitec Biopharma Heron Therapeutics Mereo BioPharma Group Alpha Teknova Annexon Lifecore Biomedical IGM Biosciences (NASDAQ:IGMS) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations. Which has more risk & volatility, IGMS or IVA? IGM Biosciences has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Do insiders & institutionals believe in IGMS or IVA? 42.8% of IGM Biosciences shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 57.0% of IGM Biosciences shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media prefer IGMS or IVA? In the previous week, Inventiva had 2 more articles in the media than IGM Biosciences. MarketBeat recorded 5 mentions for Inventiva and 3 mentions for IGM Biosciences. IGM Biosciences' average media sentiment score of 1.38 beat Inventiva's score of -0.20 indicating that IGM Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IGM Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is IGMS or IVA more profitable? Inventiva has a net margin of 0.00% compared to IGM Biosciences' net margin of -36.81%. Inventiva's return on equity of 0.00% beat IGM Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets IGM Biosciences-36.81% -125.30% -20.61% Inventiva N/A N/A N/A Do analysts rate IGMS or IVA? IGM Biosciences currently has a consensus target price of $5.50, indicating a potential upside of 319.85%. Inventiva has a consensus target price of $10.40, indicating a potential upside of 222.98%. Given IGM Biosciences' higher probable upside, research analysts clearly believe IGM Biosciences is more favorable than Inventiva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IGM Biosciences 1 Sell rating(s) 9 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.90Inventiva 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has stronger valuation and earnings, IGMS or IVA? IGM Biosciences has higher earnings, but lower revenue than Inventiva. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIGM Biosciences$2.68M29.39-$195.79M-$3.27-0.40Inventiva$9.95M30.96-$199.34MN/AN/A SummaryInventiva beats IGM Biosciences on 9 of the 14 factors compared between the two stocks. Get IGM Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for IGMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IGMS vs. The Competition Export to ExcelMetricIGM BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$76.35M$3.00B$5.49B$9.52BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-1.4617.6228.7523.81Price / Sales29.39179.21372.2066.02Price / CashN/A41.9535.4557.96Price / Book1.608.508.275.55Net Income-$195.79M-$55.06M$3.25B$259.20M7 Day Performance3.15%-3.99%-3.72%-4.64%1 Month Performance-0.76%9.58%4.30%4.41%1 Year Performance-85.03%6.70%25.87%17.95% IGM Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IGMSIGM Biosciences4.2687 of 5 stars$1.31+3.1%$5.50+319.8%-86.5%$76.35M$2.68M-1.46190News CoveragePositive NewsEarnings ReportIVAInventiva2.5144 of 5 stars$3.04-4.1%$10.40+242.1%+42.5%$302.92M$9.95M0.00100News CoveragePositive NewsShort Interest ↑Gap UpVORVor Biopharma3.2859 of 5 stars$2.42+10.0%$5.63+132.6%+123.4%$302.40MN/A-1.47140Gap DownESPREsperion Therapeutics4.0329 of 5 stars$1.59+5.3%$7.00+340.3%-35.8%$299.28M$332.31M-1.99200News CoverageUpcoming EarningsAnalyst RevisionGap DownSCPHscPharmaceuticals3.8033 of 5 stars$5.41-3.4%$14.00+158.8%+7.9%$295.64M$36.33M-2.8330News CoverageBNTCBenitec Biopharma1.5873 of 5 stars$11.02-1.4%$26.00+135.9%+30.0%$293.48M$80K-7.3020Positive NewsHRTXHeron Therapeutics3.7275 of 5 stars$1.86-2.6%$5.00+168.8%-39.9%$291.40M$144.29M-31.00300MREOMereo BioPharma Group1.3786 of 5 stars$1.76flat$7.20+309.1%-58.3%$279.84M$10M-25.1440TKNOAlpha Teknova2.2067 of 5 stars$5.14-0.8%$10.00+94.6%+19.4%$276.82M$37.74M-10.71240Upcoming EarningsANNXAnnexon2.2204 of 5 stars$2.49-0.8%$12.50+402.0%-59.8%$275.38MN/A-2.1160Gap DownLFCRLifecore Biomedical1.4653 of 5 stars$7.33-1.3%$8.00+9.1%+15.9%$275.10M$128.26M-5.06690News Coverage Related Companies and Tools Related Companies IVA Alternatives VOR Alternatives ESPR Alternatives SCPH Alternatives BNTC Alternatives HRTX Alternatives MREO Alternatives TKNO Alternatives ANNX Alternatives LFCR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IGMS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
